Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes
Background and purpose: Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and oxidative stress are reported to be involved in the development of sepsis-induced cardiomyopathy. Dulaglutide is a novel...
Saved in:
Published in | ACS omega Vol. 6; no. 12; pp. 8271 - 8278 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
30.03.2021
|
Online Access | Get full text |
ISSN | 2470-1343 2470-1343 |
DOI | 10.1021/acsomega.0c06326 |
Cover
Abstract | Background and purpose: Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and oxidative stress are reported to be involved in the development of sepsis-induced cardiomyopathy. Dulaglutide is a novel antidiabetic agent that is currently reported to exert an anti-inflammatory effect. The present study aims to explore the potential protective property of dulaglutide on lipopolysaccharide (LPS)-induced injury on cardiomyocytes. Methods: LPS was used to induce an in vitro injury model on cardiomyocytes. The mitochondrial reactive oxygen species (ROS) level was detected using MitoSOX red, and reduced glutathione (GSH) was measured to evaluate the status of oxidative stress in H9c2 myocardial cells. The expressions of NADPH oxidase-1 (NOX-1) and inducible nitric oxidesynthase (iNOS) were determined using real-time PCR and western blot analysis. Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were both used to detect the expressions and concentrations of tumor necrosis factor-α, interleukin-1β, interleukin-17, matrix metalloproteinase-2, and matrix metalloproteinase-9 in H9c2 myocardial cells, respectively. The production of nitric oxide (NO) was measured using the Griess reagent. The levels of creatine kinase isoenzyme-MB (CK-MB) and cardiac troponin I (cTnI) were detected using ELISA. Western blot was utilized to determine the expressions of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and p-NF-κB p65 in H9c2 myocardial cells in the nucleus. Results: First, dulaglutide ameliorated LPS-induced oxidative stress by suppressing the production of mitochondrial ROS and elevating the level of reduced GSH, as well as downregulating NOX-1. Second, the LPS-induced cardiomyocyte injury was alleviated by dulaglutide through downregulating CK-MB and cTnI, accompanied by inhibiting iNOS expression and NO production. Lastly, the production of inflammatory factors and upregulation of MMPs induced by LPS were both significantly reversed by dulaglutide through suppressing the TLR4/Myd88/NF-κB signaling pathway. Conclusions: Dulaglutide alleviated LPS-induced injury in cardiomyocytes by inhibiting inflammation and oxidative stress. |
---|---|
AbstractList | Background
and purpose:
Sepsis is a severe
infection-induced disease with multiple organ failure, and sepsis-induced
cardiomyopathy is a fatal condition. Inflammatory response and oxidative
stress are reported to be involved in the development of sepsis-induced
cardiomyopathy. Dulaglutide is a novel antidiabetic agent that is
currently reported to exert an anti-inflammatory effect. The present
study aims to explore the potential protective property of dulaglutide
on lipopolysaccharide (LPS)-induced injury on cardiomyocytes. Methods:
LPS was used to induce an
in vitro
injury model on
cardiomyocytes. The mitochondrial reactive oxygen species (ROS) level
was detected using MitoSOX red, and reduced glutathione (GSH) was
measured to evaluate the status of oxidative stress in H9c2 myocardial
cells. The expressions of NADPH oxidase-1 (NOX-1) and inducible nitric
oxidesynthase (iNOS) were determined using real-time PCR and western
blot analysis. Real-time PCR and enzyme-linked immunosorbent assay
(ELISA) were both used to detect the expressions and concentrations
of tumor necrosis factor-α, interleukin-1β, interleukin-17,
matrix metalloproteinase-2, and matrix metalloproteinase-9 in H9c2
myocardial cells, respectively. The production of nitric oxide (NO)
was measured using the Griess reagent. The levels of creatine kinase
isoenzyme-MB (CK-MB) and cardiac troponin I (cTnI) were detected using
ELISA. Western blot was utilized to determine the expressions of toll-like
receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and
p-NF-κB p65 in H9c2 myocardial cells in the nucleus. Results:
First, dulaglutide ameliorated LPS-induced oxidative stress by suppressing
the production of mitochondrial ROS and elevating the level of reduced
GSH, as well as downregulating NOX-1. Second, the LPS-induced cardiomyocyte
injury was alleviated by dulaglutide through downregulating CK-MB
and cTnI, accompanied by inhibiting iNOS expression and NO production.
Lastly, the production of inflammatory factors and upregulation of
MMPs induced by LPS were both significantly reversed by dulaglutide
through suppressing the TLR4/Myd88/NF-κB signaling pathway.
Conclusions: Dulaglutide alleviated LPS-induced injury in cardiomyocytes
by inhibiting inflammation and oxidative stress. Background and purpose: Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and oxidative stress are reported to be involved in the development of sepsis-induced cardiomyopathy. Dulaglutide is a novel antidiabetic agent that is currently reported to exert an anti-inflammatory effect. The present study aims to explore the potential protective property of dulaglutide on lipopolysaccharide (LPS)-induced injury on cardiomyocytes. Methods: LPS was used to induce an in vitro injury model on cardiomyocytes. The mitochondrial reactive oxygen species (ROS) level was detected using MitoSOX red, and reduced glutathione (GSH) was measured to evaluate the status of oxidative stress in H9c2 myocardial cells. The expressions of NADPH oxidase-1 (NOX-1) and inducible nitric oxidesynthase (iNOS) were determined using real-time PCR and western blot analysis. Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were both used to detect the expressions and concentrations of tumor necrosis factor-α, interleukin-1β, interleukin-17, matrix metalloproteinase-2, and matrix metalloproteinase-9 in H9c2 myocardial cells, respectively. The production of nitric oxide (NO) was measured using the Griess reagent. The levels of creatine kinase isoenzyme-MB (CK-MB) and cardiac troponin I (cTnI) were detected using ELISA. Western blot was utilized to determine the expressions of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and p-NF-κB p65 in H9c2 myocardial cells in the nucleus. Results: First, dulaglutide ameliorated LPS-induced oxidative stress by suppressing the production of mitochondrial ROS and elevating the level of reduced GSH, as well as downregulating NOX-1. Second, the LPS-induced cardiomyocyte injury was alleviated by dulaglutide through downregulating CK-MB and cTnI, accompanied by inhibiting iNOS expression and NO production. Lastly, the production of inflammatory factors and upregulation of MMPs induced by LPS were both significantly reversed by dulaglutide through suppressing the TLR4/Myd88/NF-κB signaling pathway. Conclusions: Dulaglutide alleviated LPS-induced injury in cardiomyocytes by inhibiting inflammation and oxidative stress. Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and oxidative stress are reported to be involved in the development of sepsis-induced cardiomyopathy. Dulaglutide is a novel antidiabetic agent that is currently reported to exert an anti-inflammatory effect. The present study aims to explore the potential protective property of dulaglutide on lipopolysaccharide (LPS)-induced injury on cardiomyocytes. LPS was used to induce an injury model on cardiomyocytes. The mitochondrial reactive oxygen species (ROS) level was detected using MitoSOX red, and reduced glutathione (GSH) was measured to evaluate the status of oxidative stress in H9c2 myocardial cells. The expressions of NADPH oxidase-1 (NOX-1) and inducible nitric oxidesynthase (iNOS) were determined using real-time PCR and western blot analysis. Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were both used to detect the expressions and concentrations of tumor necrosis factor-α, interleukin-1β, interleukin-17, matrix metalloproteinase-2, and matrix metalloproteinase-9 in H9c2 myocardial cells, respectively. The production of nitric oxide (NO) was measured using the Griess reagent. The levels of creatine kinase isoenzyme-MB (CK-MB) and cardiac troponin I (cTnI) were detected using ELISA. Western blot was utilized to determine the expressions of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and p-NF-κB p65 in H9c2 myocardial cells in the nucleus. First, dulaglutide ameliorated LPS-induced oxidative stress by suppressing the production of mitochondrial ROS and elevating the level of reduced GSH, as well as downregulating NOX-1. Second, the LPS-induced cardiomyocyte injury was alleviated by dulaglutide through downregulating CK-MB and cTnI, accompanied by inhibiting iNOS expression and NO production. Lastly, the production of inflammatory factors and upregulation of MMPs induced by LPS were both significantly reversed by dulaglutide through suppressing the TLR4/Myd88/NF-κB signaling pathway. Dulaglutide alleviated LPS-induced injury in cardiomyocytes by inhibiting inflammation and oxidative stress. Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and oxidative stress are reported to be involved in the development of sepsis-induced cardiomyopathy. Dulaglutide is a novel antidiabetic agent that is currently reported to exert an anti-inflammatory effect. The present study aims to explore the potential protective property of dulaglutide on lipopolysaccharide (LPS)-induced injury on cardiomyocytes.BACKGROUND AND PURPOSESepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and oxidative stress are reported to be involved in the development of sepsis-induced cardiomyopathy. Dulaglutide is a novel antidiabetic agent that is currently reported to exert an anti-inflammatory effect. The present study aims to explore the potential protective property of dulaglutide on lipopolysaccharide (LPS)-induced injury on cardiomyocytes.LPS was used to induce an in vitro injury model on cardiomyocytes. The mitochondrial reactive oxygen species (ROS) level was detected using MitoSOX red, and reduced glutathione (GSH) was measured to evaluate the status of oxidative stress in H9c2 myocardial cells. The expressions of NADPH oxidase-1 (NOX-1) and inducible nitric oxidesynthase (iNOS) were determined using real-time PCR and western blot analysis. Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were both used to detect the expressions and concentrations of tumor necrosis factor-α, interleukin-1β, interleukin-17, matrix metalloproteinase-2, and matrix metalloproteinase-9 in H9c2 myocardial cells, respectively. The production of nitric oxide (NO) was measured using the Griess reagent. The levels of creatine kinase isoenzyme-MB (CK-MB) and cardiac troponin I (cTnI) were detected using ELISA. Western blot was utilized to determine the expressions of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and p-NF-κB p65 in H9c2 myocardial cells in the nucleus.METHODSLPS was used to induce an in vitro injury model on cardiomyocytes. The mitochondrial reactive oxygen species (ROS) level was detected using MitoSOX red, and reduced glutathione (GSH) was measured to evaluate the status of oxidative stress in H9c2 myocardial cells. The expressions of NADPH oxidase-1 (NOX-1) and inducible nitric oxidesynthase (iNOS) were determined using real-time PCR and western blot analysis. Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were both used to detect the expressions and concentrations of tumor necrosis factor-α, interleukin-1β, interleukin-17, matrix metalloproteinase-2, and matrix metalloproteinase-9 in H9c2 myocardial cells, respectively. The production of nitric oxide (NO) was measured using the Griess reagent. The levels of creatine kinase isoenzyme-MB (CK-MB) and cardiac troponin I (cTnI) were detected using ELISA. Western blot was utilized to determine the expressions of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and p-NF-κB p65 in H9c2 myocardial cells in the nucleus.First, dulaglutide ameliorated LPS-induced oxidative stress by suppressing the production of mitochondrial ROS and elevating the level of reduced GSH, as well as downregulating NOX-1. Second, the LPS-induced cardiomyocyte injury was alleviated by dulaglutide through downregulating CK-MB and cTnI, accompanied by inhibiting iNOS expression and NO production. Lastly, the production of inflammatory factors and upregulation of MMPs induced by LPS were both significantly reversed by dulaglutide through suppressing the TLR4/Myd88/NF-κB signaling pathway.RESULTSFirst, dulaglutide ameliorated LPS-induced oxidative stress by suppressing the production of mitochondrial ROS and elevating the level of reduced GSH, as well as downregulating NOX-1. Second, the LPS-induced cardiomyocyte injury was alleviated by dulaglutide through downregulating CK-MB and cTnI, accompanied by inhibiting iNOS expression and NO production. Lastly, the production of inflammatory factors and upregulation of MMPs induced by LPS were both significantly reversed by dulaglutide through suppressing the TLR4/Myd88/NF-κB signaling pathway.Dulaglutide alleviated LPS-induced injury in cardiomyocytes by inhibiting inflammation and oxidative stress.CONCLUSIONSDulaglutide alleviated LPS-induced injury in cardiomyocytes by inhibiting inflammation and oxidative stress. |
Author | Wang, Ning Wang, Rijun Han, Yuping Xu, Zesheng Xu, Jiyao |
AuthorAffiliation | Cangzhou Central Hospital Affiliated of Tianjin Medical University Department of Cornea Shanxi Ophthalmic Hospital Shanxi Cardiovascular Hospital Department of Cardiology |
AuthorAffiliation_xml | – name: Department of Cardiology – name: Shanxi Ophthalmic Hospital – name: Shanxi Cardiovascular Hospital – name: Department of Cornea – name: Cangzhou Central Hospital Affiliated of Tianjin Medical University |
Author_xml | – sequence: 1 givenname: Rijun surname: Wang fullname: Wang, Rijun organization: Shanxi Cardiovascular Hospital – sequence: 2 givenname: Ning surname: Wang fullname: Wang, Ning organization: Shanxi Cardiovascular Hospital – sequence: 3 givenname: Yuping surname: Han fullname: Han, Yuping organization: Shanxi Ophthalmic Hospital – sequence: 4 givenname: Jiyao surname: Xu fullname: Xu, Jiyao organization: Shanxi Cardiovascular Hospital – sequence: 5 givenname: Zesheng orcidid: 0000-0001-6435-2724 surname: Xu fullname: Xu, Zesheng email: xuzesheng1966@163.com organization: Cangzhou Central Hospital Affiliated of Tianjin Medical University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33817486$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtr3DAUhUVJaB7NvqviZRd1qoctSxQKYdq0AwMJtF2L62tpqkG2UskOzL-vk5mEpNCs9LjnfPdK54QcDHGwhLxl9JxRzj4C5tjbNZxTpFJw-Yoc86qhJROVOHiyPyJnOW8opUwqrrh8TY6EUKyplDwmn75MAdZhGn1ni4sQ7K2H0eZidf2jXA7dhLYrlsNmStvCD8UCUudjv424nUVvyKGDkO3Zfj0lvy6__lx8L1dX35aLi1UJldZjaZmQTjqhhW7qCkBa23BdO1S2rVAgqFoAco2Ou_mgKpScuhYloGOtpuKULHfcLsLG3CTfQ9qaCN7cX8S0NpBGj8GaGjvGGt20rrFVDaCFU6jrhjeUA7RuZn3esW6mtrcd2mFMEJ5Bn1cG_9us461RlNXzQ2bA-z0gxT-TzaPpfUYbAgw2Ttnwmiqlpbqf-93TXo9NHn5_FtCdAFPMOVn3KGHU3GVsHjI2-4xni_zHgn6E0ce7aX14yfhhZ5wrZhOnNMyR_V_-F3pmvY8 |
CitedBy_id | crossref_primary_10_1536_ihj_23_576 crossref_primary_10_1615_CritRevImmunol_2023050050 crossref_primary_10_1016_j_heliyon_2023_e13330 crossref_primary_10_1016_j_jafr_2024_101034 crossref_primary_10_3389_fphar_2022_868393 crossref_primary_10_1002_cbdv_202401224 crossref_primary_10_1007_s00011_024_01950_0 crossref_primary_10_1007_s00210_024_03631_5 crossref_primary_10_1002_ptr_7693 crossref_primary_10_1007_s00394_024_03549_x crossref_primary_10_1002_fft2_441 crossref_primary_10_1161_JAHA_122_026728 crossref_primary_10_3390_molecules27155037 crossref_primary_10_3390_ph17040525 crossref_primary_10_3390_pharmaceutics16060693 crossref_primary_10_1186_s12933_022_01634_1 crossref_primary_10_1186_s10020_024_00912_w crossref_primary_10_1016_j_jff_2022_105304 crossref_primary_10_1038_s41420_022_01287_9 |
Cites_doi | 10.1097/aln.0000000000000398 10.5152/tjg.2014.4716 10.1016/j.ccm.2008.07.002 10.1002/jcb.21338 10.1016/j.intimp.2019.05.034 10.1074/jbc.m112.412031 10.1016/j.bbadis.2018.10.011 10.1097/shk.0000000000000978 10.26355/eurrev_201906_18094 10.3389/fimmu.2017.01021 10.1097/shk.0b013e3182391831 10.1155/2014/157376 10.1111/dom.12479 10.1007/s00125-011-2440-x 10.1016/j.intimp.2019.105898 10.7754/clin.lab.2016.160533 10.1056/nejm198908033210503 10.1159/000491887 10.1152/ajpcell.00356.2016 10.1186/s12933-014-0142-7 10.1186/s12933-020-01179-1 10.1001/jama.2016.0287 10.1152/ajpheart.00995.2008 10.1016/0014-5793(94)01430-9 10.1016/S0140-6736(19)31149-3 10.3760/cma.j.issn.2095-4352.2018.07.017 10.1016/j.abb.2019.07.008 10.1016/j.molmed.2007.09.002 10.1080/14712598.2017.1296131 10.7326/0003-4819-100-4-483 10.3389/fphar.2020.00090 |
ContentType | Journal Article |
Copyright | 2021 The
Authors. Published by American Chemical Society 2021 The Authors. Published by American Chemical Society. 2021 The Authors. Published by American Chemical Society 2021 The Authors |
Copyright_xml | – notice: 2021 The Authors. Published by American Chemical Society – notice: 2021 The Authors. Published by American Chemical Society. – notice: 2021 The Authors. Published by American Chemical Society 2021 The Authors |
DBID | N~. AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.1021/acsomega.0c06326 |
DatabaseName | American Chemical Society (ACS) Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: N~. name: American Chemical Society (ACS) Open Access url: https://pubs.acs.org sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry |
EISSN | 2470-1343 |
EndPage | 8278 |
ExternalDocumentID | oai_doaj_org_article_5cd11797bf7e45aa93f8c9572702aabf PMC8015136 33817486 10_1021_acsomega_0c06326 a312506758 |
Genre | Journal Article |
GroupedDBID | 53G ABFRP ABUCX ACS ACSAX ADACO ADBBV AFEFF ALMA_UNASSIGNED_HOLDINGS BCNDV EBS GROUPED_DOAJ HYE N~. OK1 RPM VF5 AAFWJ AAHBH AAYXX ABBLG ADUCK AFPKN AOIJS CITATION M~E NPM 7X8 5PM |
ID | FETCH-LOGICAL-a499t-e136f6f3939754aa6ee7295fc8eb4c3ca853ac29cf2fca884c620fbc6acf1b903 |
IEDL.DBID | DOA |
ISSN | 2470-1343 |
IngestDate | Wed Aug 27 01:19:04 EDT 2025 Thu Aug 21 14:14:06 EDT 2025 Fri Jul 11 07:36:32 EDT 2025 Wed Feb 19 02:26:04 EST 2025 Thu Apr 24 23:00:49 EDT 2025 Tue Jul 01 01:05:51 EDT 2025 Sun Apr 11 09:01:11 EDT 2021 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Language | English |
License | https://creativecommons.org/licenses/by-nc-nd/4.0 2021 The Authors. Published by American Chemical Society. Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a499t-e136f6f3939754aa6ee7295fc8eb4c3ca853ac29cf2fca884c620fbc6acf1b903 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-6435-2724 |
OpenAccessLink | https://doaj.org/article/5cd11797bf7e45aa93f8c9572702aabf |
PMID | 33817486 |
PQID | 2508896890 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_5cd11797bf7e45aa93f8c9572702aabf pubmedcentral_primary_oai_pubmedcentral_nih_gov_8015136 proquest_miscellaneous_2508896890 pubmed_primary_33817486 crossref_primary_10_1021_acsomega_0c06326 crossref_citationtrail_10_1021_acsomega_0c06326 acs_journals_10_1021_acsomega_0c06326 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-03-30 |
PublicationDateYYYYMMDD | 2021-03-30 |
PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-30 day: 30 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | ACS omega |
PublicationTitleAlternate | ACS Omega |
PublicationYear | 2021 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | ref9/cit9 ref6/cit6 ref3/cit3 ref27/cit27 ref18/cit18 ref11/cit11 ref25/cit25 ref16/cit16 ref29/cit29 ref32/cit32 ref23/cit23 ref14/cit14 ref8/cit8 ref5/cit5 ref31/cit31 ref2/cit2 ref28/cit28 ref20/cit20 ref17/cit17 ref10/cit10 ref26/cit26 ref19/cit19 ref21/cit21 ref12/cit12 ref15/cit15 ref22/cit22 ref13/cit13 ref4/cit4 ref30/cit30 ref1/cit1 ref24/cit24 ref7/cit7 35694462 - ACS Omega. 2022 May 26;7(22):19040 |
References_xml | – ident: ref10/cit10 doi: 10.1097/aln.0000000000000398 – ident: ref18/cit18 doi: 10.5152/tjg.2014.4716 – ident: ref5/cit5 doi: 10.1016/j.ccm.2008.07.002 – ident: ref22/cit22 doi: 10.1002/jcb.21338 – ident: ref14/cit14 doi: 10.1016/j.intimp.2019.05.034 – ident: ref21/cit21 doi: 10.1074/jbc.m112.412031 – ident: ref16/cit16 doi: 10.1016/j.bbadis.2018.10.011 – ident: ref2/cit2 doi: 10.1097/shk.0000000000000978 – ident: ref25/cit25 doi: 10.26355/eurrev_201906_18094 – ident: ref6/cit6 doi: 10.3389/fimmu.2017.01021 – ident: ref23/cit23 doi: 10.1097/shk.0b013e3182391831 – ident: ref11/cit11 doi: 10.1155/2014/157376 – ident: ref32/cit32 doi: 10.1111/dom.12479 – ident: ref28/cit28 doi: 10.1007/s00125-011-2440-x – ident: ref24/cit24 doi: 10.1016/j.intimp.2019.105898 – ident: ref19/cit19 doi: 10.7754/clin.lab.2016.160533 – ident: ref9/cit9 doi: 10.1056/nejm198908033210503 – ident: ref17/cit17 doi: 10.1159/000491887 – ident: ref20/cit20 doi: 10.1152/ajpcell.00356.2016 – ident: ref26/cit26 doi: 10.1186/s12933-014-0142-7 – ident: ref13/cit13 doi: 10.1186/s12933-020-01179-1 – ident: ref1/cit1 doi: 10.1001/jama.2016.0287 – ident: ref7/cit7 doi: 10.1152/ajpheart.00995.2008 – ident: ref27/cit27 doi: 10.1016/0014-5793(94)01430-9 – ident: ref29/cit29 doi: 10.1016/S0140-6736(19)31149-3 – ident: ref3/cit3 doi: 10.3760/cma.j.issn.2095-4352.2018.07.017 – ident: ref30/cit30 doi: 10.1016/j.abb.2019.07.008 – ident: ref31/cit31 doi: 10.1016/j.intimp.2019.05.034 – ident: ref8/cit8 doi: 10.1016/j.molmed.2007.09.002 – ident: ref12/cit12 doi: 10.1080/14712598.2017.1296131 – ident: ref4/cit4 doi: 10.7326/0003-4819-100-4-483 – ident: ref15/cit15 doi: 10.3389/fphar.2020.00090 – reference: 35694462 - ACS Omega. 2022 May 26;7(22):19040 |
SSID | ssj0001682826 |
Score | 2.3041065 |
Snippet | Background and purpose: Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition.... Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and... Background and purpose: Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition.... |
SourceID | doaj pubmedcentral proquest pubmed crossref acs |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 8271 |
SummonAdditionalLinks | – databaseName: American Chemical Society Journals dbid: ACS link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwELWgHOBSvunypSDBgUO2ju04sTiVhaogQEilUm-WPbFL220Wkd1D--s7481u2VJVPSaxE9sz1jzH4_cYe2skhk0BPK9Jw500rHMPIuTeA3jQVeRJDuj7D72zp77ul_sXNDmXd_BFsemgm5yEAzfkgOFU6NvsjtAYZggGjXYv_qdoXDskdTWhKp4XUsl-V_Kql1Asgm4lFiXK_qtw5uV0yX_iz_b9uZBRl2gLKe3keDib-iGc_U_qeIOuPWDrPQzNtuZ-85DdCu0jdne0UH97zD58mo3dAbllE7KtMR1CJ1Saffu5m5PcB4Qm-9IeoUWywzYbpazWk9MJnGKhJ2xv-_Ov0U7eCy3kDhc80zwUUkcdpUFwUirndAiIuSm7K3gFEhzGdAfCQBQRL2oFWvCIpnQQC2-4fMrW2kkbNljmQjQE22LQQTVNND7ZpXE1LxtXFAP2Dntt-4nS2bQHLgq7GArbD8WAbS5MY6FnKyfRjPE1Nd4va_yZM3VcU_YjWXtZjji20w20ju2nrC2hIb68yscqqNI5I2MNpqzoBJ9zPg7Ym4WvWDQObbS4NkxmnRWEeo2uDR-wZ3PfWX5KEiWiqrEJ1YpXrbRl9Ul7-DvxfiOYKNFSz284hC_YPUEJOHSAkr9ka9O_s_AKEdTUv05T5xxnwxgY priority: 102 providerName: American Chemical Society |
Title | Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes |
URI | http://dx.doi.org/10.1021/acsomega.0c06326 https://www.ncbi.nlm.nih.gov/pubmed/33817486 https://www.proquest.com/docview/2508896890 https://pubmed.ncbi.nlm.nih.gov/PMC8015136 https://doaj.org/article/5cd11797bf7e45aa93f8c9572702aabf |
Volume | 6 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagF7gg3iyPKkhw4JCu4yROLE5laVUQrZBKpd6s8cQuRdts1d099NLfzoyTrHYRKhculuLYymhmkvkcj78R4p3JKWwqlGnNNdy5hnXqUPnUOUSHugoylgM6PNIHJ8XX0_J0rdQX54R19MCd4sYlNsxaVrlQ-aIEMHmo0ZQVn6MCcIG_vtLItcVU_LuiaSWhhn1JimNjwPnswp_BjkSKysylcJe6NqJRJO3_G9L8M2FyLQLtPxQPeuiY7HYiPxJ3fPtY3JsMFdueiI-fl1M4Y1dqfLI75YPjjCSTb9-PUy7Rgb5JvrS_SIvJeZtMYibqxfUMr2nQU3Gyv_djcpD2xRFSoEXKIvVZroMOuSFAURYA2nvCyZyR5V2BOQLFYUBlMKhAF3WBWslA6gcMmTMyfya22lnrX4gEfDAMtYLXvmiaYFzUXgO1LBvIspF4T6qyvXPPbdy3VpkdVGp7lY7EeFCmxZ5hnAtdTG-Z8WE147Jj17hl7Ce2z2oc82LHDvIW23uL_Ze3jMTbwbqWjMObI9D62XJuFSNVo2sjR-J5Z-3Vo3KmMSxqEqHa8IMNWTbvtOc_I1c3AYCSLPXyfwj_StxXnFHDJyLla7G1uFr6NwSJFm6blgST4-34DlB7eLNH7dHNzm_MgA_C |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwELVKOZQL35TlM0hw4JBt4jhOLE7LQrWFbYVoK_Vm2RO7lG6zFdk9lF_PjDfZslVVwTGOk9ieseY5Hr_H2FuVYdjkkMQlabiThnVsgbvYWgALsvBJkAPa3ZOjQ_HlKD9aY2l3FgYb0eCbmrCJf8kukG5h2fTMHZt-AhhVubzFbudSSFJrGAz3L3-rSFxCBJE1LookTjORtZuT172EQhI0KyEpMPdfBzevZk3-FYa277Hvyw6E7JPT_nxm-_D7Crfjf_XwPrvbgtJosPCiB2zN1Q_ZxrDTgnvEPnyaT8wxOWnlosGEjqQTRo3G3_ZjEv8AV0U79U-0T3RSR8OQ43p2MYULrPSYHW5_PhiO4lZ2ITa4_JnFLs2klz5TCFVyYYx0DhE45Xo5KyADgxHeAFfguceLUoDkiUfDGvCpVUn2hK3X09o9ZZFxXhGI8046UVVe2WCeypRJXpk07bF32GvdTptGhx1xnupuKHQ7FD221VlIQ8tdThIakxueeL984nzB23FD3Y9k9GU9YtwOBWgh3U5gnUNF7HmF9YUTuTEq8yWovKDzfMZY32NvOpfRaBzadjG1m84bzQkDK1mqpMc2Fy60_FRGBImixCYUK8610pbVO_XJj8ACjtAiR0s9-8chfM02Rge7Yz3e2fv6nN3hlJpDRyuTF2x99mvuXiK2mtlXYTb9Ad79IHo |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwEB2VIgEXvgvLZ5DgwCHbxEmcWJyWLasWSlWpFPVm2RO7FLbZiuweyq9nxptd2Kqq4BjHSWzPWPMcj98DeK0yCpsCk7hiDXfWsI4tChdbi2hRlj4JckCf9-T2Yf7xqDhag2JxFoYa0dKb2rCJz7P6rPYdw0C6SeWTU3ds-glSZBXyGlwnPJKyYsNgePDn14qkZUQQWhN5mcRplmfdBuVlL-GwhO1KWArs_ZdBzouZk3-FotEd-LrsRMhA-dGfTW0ff13gd_zvXt6F2x04jQZzb7oHa665DzeHC024B_BuazY2x-ystYsGYz6azlg12t0_iFkEBF0d7TTfyU7RSRMNQ67r6fkEz6nSQzgcffgy3I47-YXY0DJoGrs0k176TBFkKXJjpHOExDnny9kcMzQU6Q0KhV54uqhylCLxZGCDPrUqyTZgvZk07jFExnnFYM476fK69soGE9WmSorapGkP3lCvdTd9Wh12xkWqF0Ohu6HowebCSho7DnOW0hhf8cTb5RNnc_6OK-q-Z8Mv6zHzdiggK-luIusCa2bRK60vXV4YozJfoSpKPtdnjPU9eLVwG03G4e0X07jJrNWCsbCSlUp68GjuRstPZUyUmFfUhHLFwVbasnqnOfkW2MAJYhRkqSf_OIQv4cb-1kjv7ux9egq3BGfo8AnL5BmsT3_O3HOCWFP7Ikyo3-1zIvQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dulaglutide+Alleviates+LPS-Induced+Injury+in+Cardiomyocytes&rft.jtitle=ACS+omega&rft.au=Wang%2C+Rijun&rft.au=Wang%2C+Ning&rft.au=Han%2C+Yuping&rft.au=Xu%2C+Jiyao&rft.date=2021-03-30&rft.issn=2470-1343&rft.eissn=2470-1343&rft.volume=6&rft.issue=12&rft.spage=8271&rft.epage=8278&rft_id=info:doi/10.1021%2Facsomega.0c06326&rft.externalDBID=n%2Fa&rft.externalDocID=10_1021_acsomega_0c06326 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2470-1343&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2470-1343&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2470-1343&client=summon |